Ursula Wiedermann

Title: Ursula Wiedermann: Innovator in Vaccine Development

Introduction

Ursula Wiedermann is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of vaccine development, particularly in the context of cancer treatment. With a total of 3 patents to her name, her work focuses on innovative vaccine compositions that aim to enhance humoral responses against specific cancer markers.

Latest Patents

Wiedermann's latest patents include a vaccine composition designed to raise a humoral response to PD1, which is crucial for treating cancers characterized by PD1 involvement. This vaccine composition comprises an effective amount of an immunogen that induces an antibody response targeting a B cell epitope of PD1. Another notable patent involves a vaccine composition that includes an adjuvant and at least one fusion peptide conjugated to a carrier protein, specifically the diphtheria toxin variant CRM-197. This invention aims to treat or prevent cancers characterized by the expression or over-expression of Her2/neu.

Career Highlights

Throughout her career, Ursula Wiedermann has worked with various companies, including Biomay AG and Imugene Ltd. Her expertise in vaccine development has positioned her as a key figure in the biotechnology sector, contributing to advancements in cancer immunotherapy.

Collaborations

Wiedermann has collaborated with notable professionals in her field, including Hans Groenlund and Johan Roennelid. These partnerships have further enriched her research and development efforts in vaccine technology.

Conclusion

Ursula Wiedermann's innovative work in vaccine development showcases her commitment to advancing cancer treatment through scientific research. Her contributions continue to impact the field positively, paving the way for future breakthroughs in immunotherapy.